- Home
- AUTL vs CD Comparison
AUTL vs CD Comparison
Compare AUTL & CD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AUTL | CD |
|---|---|---|
| Founded | 2014 | 2011 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Computer Software: Programming Data Processing |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 335.4M | 323.4M |
| IPO Year | 2025 | 2014 |
Fundamental Metrics
Financial Performance| Metric | AUTL | CD |
|---|---|---|
| Price | $1.18 | $4.37 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $8.36 | N/A |
| AVG Volume (30 Days) | ★ 2.5M | 336.6K |
| Earning Date | 11-10-2026 | 08-31-2023 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $10,120,000.00 | $1,867,068.00 |
| Revenue This Year | $101.75 | N/A |
| Revenue Next Year | $29.27 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 496.00 | 277.93 |
| 52 Week Low | $1.12 | $2.10 |
| 52 Week High | $2.58 | $14.10 |
Technical Indicators
Market Signals| Indicator | AUTL | CD |
|---|---|---|
| Relative Strength Index (RSI) | 24.83 | 36.74 |
| Support Level | N/A | $2.91 |
| Resistance Level | $1.71 | $4.35 |
| Average True Range (ATR) | 0.11 | 1.25 |
| MACD | -0.02 | -0.39 |
| Stochastic Oscillator | 9.43 | 7.38 |
Price Performance
Historical ComparisonAbout AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.
About CD Chaince Digital Holdings Inc. Ordinary Shares
Chaince Digital Holdings Inc is digital fintech company providing access to the growing AI-powered infrastructure, blockchain, and digital assets. Its three core business lines include: blockchain and digital asset solutions, AI and HPC infrastructure, developing liquid cooling solutions for AI data centers and comprehensive financial services through Chaince Securities,LLC a FINRA-registered broker-dealer, and RIA.